| Home | Generics | Biosimilars | Docs & Positions | Facts & Figures | Press Room | Conferences | Links |
Making Medicines affordable.News RoomLatest NewsPress ReleasesReleases 2010Releases 2009Releases 2008Releases 2007Releases 2006 Releases 2005 Releases 2004 Releases 2003 Media KitHandy Info |
EGA News RoomLatest News from EGAPRESS RELEASE | 2 September 2010 EGA CALLS FOR A WORKABLE GUIDELINE FOR BIOSIMILAR MONOCLONAL ANTIBODIES AND A CONSISTENT SCIENTIFIC GLOBAL APPROACH TOWARDS BIOSIMILAR MEDICINESIn his opening address to the 8th EGA International Symposium on Biosimilar Medicines today in London, EGA Director General Greg Perry praised the EU for continuing to inspire the rest of the world regarding the development of scientific biosimilar guidelines. “If healthcare systems are to continue to function long-term”, he said, “we must address the importance of biosimilar monoclonal antibodies next. Science for monoclonal antibodies is already here today and our industry is expecting a workable guideline”. More... PRESS RELEASE | 8 July 2010 INAUGURATION AT CATHOLIC UNIVERSITY OF LEUVEN: EGA CHAIR “EUROPEAN POLICY TOWARDS GENERIC MEDICINES” PRESS RELEASE | 1 July 2010 ECJ DECISION HELPS TO ENSURE PATIENT ACCESS TO GENERIC MEDICINESThe European Generic medicines Association has welcomed the Decision from the European Court of Justice, which has endorsed the European Commission’s findings that Astra Zeneca abused its dominant position in the market for proton pump inhibitors. The Court confirmed there was clear evidence of anti-competitive activity, through misuse of the patent and regulatory systems, in order to delay the entry of generic Omeprazol, the active ingredient in the company’s blockbuster drug, Losec. PRESS RELEASE | 3 June 2010 ONLY A SUSTAINABLE GENERIC MEDICINES INDUSTRY WILL MAXIMISE HEALTHCARE SYSTEMS BENEFITS IN EUROPE“Increasing generic medicines market penetration is the fastest way towards considerable and sustainable savings for healthcare systems in Europe”. This is the key message delivered by EGA President Didier Barret to delegates at the EGA’s Annual General Meeting in Rome on 3 and 4 June 2010. More... PRESS RELEASE | 1 June 2010 3RD EGA BIOEQUIVALENCE FORUM IN LONDON CONTINUES SUCCESSFUL COOPERATION WITH THE EU MEDICINES AUTHORITIES ON EU GUIDELINESThe EGA’s 3rd Bioequivalence Forum is set to focus exclusively on the revised Guideline on the Investigation of Bioequivalence PRESS RELEASE | 6 May 2010 OPEN LETTER TO THE SPANISH HEALTH AND SOCIAL POLICY MINISTER: Price cuts must be followed by increase in patient access to generic medicinesPRESS RELEASE | 27 April 2010 EGA WELCOMES COMMITTEE ADOPTION OF FALSIFIED MEDICINES AND PHARMACOVIGILANCE REPORTS BY MEPS“Today’s vote on falsified medicines has ensured that patient safety will be strongly secured by focusing anti-counterfeiting measures on high priced-high risk products. The European Parliament’s ENVI committee’s decision has also ensured that all safety features designed to secure the legitimate supply chain will be cost-effective, whilst guaranteeing the independence of databases. Moreover the MEPs have correctly focused measures to tackle the sale of counterfeited medicines on the internet where the major problem lies” says Greg Perry, EGA director general, commenting on the ENVI vote. More... PRESS RELEASE | 25 March 2010 EU MUST BACK GENERIC MEDICINES TO SAFEGUARD THE FUTURE OF HEALTHCARE“It is time for European policy makers to take actions to ensure a long term healthy generic business in Europe.” This call was issued in the opening statement of Greg Perry, EGA director general, at the 2nd Sustainability Conference organised by the EGA in Brussels today. More... PRESS RELEASE | 23 March 2010 IMS REPORT HIGHLIGHTS IMPORTANCE OF GENERIC MEDICINES INDUSTRY SUSTAINABILITY FOR THE EUThe sustainability of the generic medicines sector is vital to ensure accessibility and affordability of modern day pharmaceuticals in global healthcare systems. This is the conclusion drawn in a report from IMS Health published yesterday, and welcomed by the European Generic medicines Association (EGA). More... PRESS RELEASE | 11 March 2010 EGA SEEKS URGENT PATENT SYSTEM REFORM AND WELCOMES FOLLOW UP TO THE SECTOR INQUIRY"If the patent system is not reformed in Europe, drug manufacturers will encounter increasing hurdles to competition and real innovation." This was the message delivered by Greg Perry, director general of the EGA, in his opening address to delegates at the 6th EGA legal affairs forum on 11 March 2010, in Munich, Germany. More... PRESS RELEASE | 3 March 2010 MEPS LAUNCHED DISCUSSION ON NEW CONTROLS OF ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)“New controls of Active Pharmaceutical Ingredients (APIs) must be workable, effective and ensure continuous supply of all medicines”. This was the key message of Greg Perry director general of the European Generic medicines Association (EGA) at the round table hosted by MEP Judith Merkies and MEP Marisa Matias on “Effective Controls against Falsification in Active Pharmaceutical Ingredients and Excipients” in the European Parliament on 2 March. More... PRESS RELEASE | 21 January 2010 EGA CALLS FOR IMPROVED REGULATORY FRAMEWORK WITH VISION 2015 TO CREATE A STRONGER EUROPEAN GENERIC MEDECINE INDUSTRY AND INCREASED PATIENT ACCESS TO AFFORDABLE HEALTHCARE.Greg Perry, director general of the European Generic medicines Association (EGA) opened the 9th edition of the EGA Scientific and Regulatory Affairs Conference in London, by reiterating the association’s vision to create an improved European regulatory framework for generic and biosimilar medicines. More... PRESS RELEASE | 20 January 2010 KEEP IN MIND THE OBJECTIVES OF THE EC PHARMACOVIGILANCE LEGISLATIVE PROPOSALS: IMPROVING THE EU PHARMACOVIGILANCE SYSTEM AND CUTTING RED TAPE.During the ongoing codecision procedure, policy makers must keep in mind the objectives of the European Commission pharmacovigilance legislative proposals which consist in strengthening, but also streamlining and rationalising, the Community pharmacovigilance system with a view to preventing unnecessary patient exposure to risks. This was the key message given by Suzette Kox, EGA Senior Director Scientific Affairs, at the EGA’s 3rd Pharmacovigilance Discussion Forum in London today. A number of national competent authorities and the European Consumers’ Organisation participated in the forum. More... PRESS RELEASE | 18 NOVEMBER 2009 “STAKES ARE HIGHER THAN EVER FOR THE IMMEDIATE THREE YEARS AHEAD” SAYS DIDIER BARRET NEWLY ELECTED PRESIDENT OF THE EUROPEAN GENERIC MEDICINES ASSOCIATION (EGA)The European Generic medicines Association (EGA) welcomes Didier Barret as its new President, unanimously elected by the EGA Board of Directors today in Brussels. More... PRESS RELEASE | 10 NOVEMBER 2009 STOP FAKE MEDICINES: FOCUS ON SUPPLY CHAIN INTEGRITY AND CRIMINALISATION SAY MEPS AND EXPERTSPolicy makers must shift the focus away from technological measures to stop counterfeiting of medicines and look at real and effective solutions such as implementing and increasing criminal sanctions while ensuring that all parties do business only with certified and reliable partners. More.. PRESS RELEASE | 2 OCTOBER 2009 THE EU PHARMACEUTICAL SECTOR INQUIRY RECOMMENDATIONS - NOT TENDERING SYSTEMS - PROVIDE THE KEY TO INCREASING PATIENT ACCESS TO AFFORDABLE GENERIC MEDICINESTendering is undermining the long-term patient access to generic medicines” and “it is urgent that governments start to see that pricing and reimbursement measures must be about more than just short term price decreases”, said Eric Gorka EGA President More.. PRESS RELEASE | 30 SEPTEMBER 2009 BEHAVIOURAL MEASURES ARE KEY IN PROTECTING PATIENTS AGAINST COUNTERFEITED MEDICINES IN EUROPEThe European Generic medicines Association (EGA) believes that the fight against counterfeiting should primarily focus on behavioural measures that ensure patients’ and supply chain security, by harmonising criminal law among member states. PRESS RELEASE | 25 September 2009 QUICK IMPLEMENTATION OF SECTOR INQUIRY RECOMMENDATIONS IS THE ROADMAP FOR BUILDING SUSTAINABLE HEALTHCARE SYSTEMS IN SOUTH EAST EUROPE"National agencies from the South East European region should intensify cooperation and harmonisation and look at strengthening their regulatory framework. Quick alignment with the recommendations of the European Commission’s pharmaceutical sector inquiry report is the roadmap for building a sustainable pharmaceutical sector throughout Europe” says EGA director general, Greg Perry opening the 5th EGA South East Europe Pharmaceutical Symposium in Ohird, Macedonia. More... PRESS RELEASE | 8 July 2009 EUROPEAN COMMISSION INQUIRY RECOMMENDS SYSTEMIC IMPROVEMENTS TO ENSURE IMMEDIATE ACCESS FOR PATIENTS TO AFFORDABLE GENERIC MEDICINES UPON PATENT EXPIRYThe EGA welcomes the European Commission’s Final Report on the Pharmaceutical Sector Inquiry and calls on European and national authorities for quick implementation of the conclusions and recommendations. More... PRESS RELEASE | 4 June 2009 REPORT PROPOSES MEASURES TO INCREASE PATIENT ACCESS TO GENERIC MEDICINES“EU governments need to ensure fast generic medicines uptake, as market access and low market volume in key EU countries is still a real problem and is having a major negative impact on patient access to more affordable treatments”. This is the key message Greg Perry, director general of the EGA, made at the European Generic medicines Association’s 15th EGA Annual Conference at Barcelona during the launch of a new EGA report... PRESS RELEASE | 23 April 2009 TOWARDS GLOBAL DEVELOPMENT AND MONOCLONAL ANTIBODIES | TAKING BIOSIMILAR MEDICINES TO THE NEXT LEVELEGA Director General Greg Perry today congratulated industry and medicines regulators on the EU’s ‘biosimilar thinking’. “The EU continues to lead worldwide in developing new guidelines and is now taking biosimilar medicines to the next level", he said. PRESS RELEASE | 8 April 2009 EGA SEEKS BALANCE BETWEEN PATENTS AND THE PUBLIC INTEREST IN PROPOSED EU “UNIFIED PATENT LITIGATION SYSTEM”The EGA welcomes the European Commission’s initiative for a Unified Patent Litigation System, while recommending safeguards to ensure a fairer balance between patent holders and the public interest. PRESS RELEASE | 1 April 2009 PRESSURES ON GENERIC MEDICINES PUT EU HEALTHCARE AT RISKGreg Perry, director general of EGA, warns that "the future of the European generic medicines industry is under serious threat, which places both the sustainability of European healthcare and European industrial competitiveness at serious risk.” EGA PublicationsEGA PUBLICATION | June 2010 EGA Conference Highlights | 06The key moments and messages from the conferences organised by the EGA during the first quarter of 2010. EGA PUBLICATION | September 2009 EGA Conference Highlights | 05The key moments and messages from the conferences organised by the EGA during the first half of 2009. EGA PUBLICATION | June 2009 EGA Conference Highlights | 04Competitive, Cost-Effective Generic Medicines Struggle to Overcome Major Hurdles: The key moments and messages from the conferences organised by the EGA during the first half of 2009. EGA PUBLICATION: January 2009 EGA Conference highlights | 03 [2755 Kb]European Generic Medicines Industry and Regulators Build
Dialogue for Increased Understanding & Cooperation EGA PUBLICATION: December 2008 EGA Conference highlights | 02 [315 Kb]“Mutual Trust and Commitment: Working Together Towards
Sustainable Healthcare for EU Citizens” EGA PUBLICATION: March 2008 EGA Conference highlights | 01 [260 Kb]“The EGA and EU Medicines Authorities Vow Joint Effort to Develop Greater Regulatory Efficiency for Generic Medicines” EGA PUBLICATION: September 2006 EGA FOCUS on Generic Medicines | 05 [750 Kb]• Missing Out on Generic Savings? • EGA in the Pharma Forum EGA PUBLICATION: April 2006 EGA FOCUS on Generic Medicines | 04 [1 Mb]• KUL Report on Measures to Promote Generics • Patent Linkage EGA PUBLICATION: November 2005 EGA FOCUS on Generic Medicines | 03 [1 Mb]• Pricing & Reimbursement • Ensuring Quality, Safety & Efficacy EGA PUBLICATION: February 2005 EGA FOCUS on Generic Medicines | 02 [700 Kb]• Fractured Markets • Sustainable Healthcare • Compulsory Licensing EGA PUBLICATION: December 2004 EGA FOCUS on Generic Medicines | 01 [700 Kb]• Paediatric Medicines • Generic Competition • Biogenerics EGA e-News ArchiveE-NEWS EGA e-News: 25 April 2005E-NEWS: EGA e-News: 15 March 2005Media KitComplete information about the EGA and its members designed to meet the needs of busy members of the press. Please check the Media Kit frequently for handy information and the latest news. Then feel free to contact EGA for any further questions you may have. |
EGA
Conference
|
| Copyright © 2004 EGA - European Generic medicines Association • • Cascading Pop-up Menus ©Angus Turnbull |